proguanil has been researched along with Cancer of Ovary in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, X; Li, G; Wu, J; Wu, T; Wu, Y; Xiao, D; Xu, S; Yan, X; Yang, X | 1 |
1 other study(ies) available for proguanil and Cancer of Ovary
| Article | Year |
|---|---|
Proguanil synergistically sensitizes ovarian cancer cells to olaparib by increasing DNA damage and inducing apoptosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; DNA Damage; Drug Synergism; Female; Humans; Ovarian Neoplasms; Phthalazines; Piperazines; Proguanil | 2022 |